Kuros Biosciences

Are you striving for a 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘀𝗽𝗶𝗻𝗮𝗹 𝗳𝘂𝘀𝗶𝗼𝗻? The unique NeedleGrip™ surface technology of MagnetOs™ enables bone formation without added cells or growth factors. ¹˒²˒†˒‡ P-15 Peptide bone grafts have not demonstrated the same ability. ³⁻⁶˒† Learn what leading surgeons have to say about their experiences using MagnetOs  → https://lnkd.in/gG4uKwuW Read about the science behind MagnetOs and our NeedleGrip surface technology  → https://lnkd.in/e5GvEf5s

Are you a surgeon concerned about 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁 𝗺𝗶𝗴𝗿𝗮𝘁𝗶𝗼𝗻? 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀ᵀᴹ 𝗶𝘀 𝗮 𝗯𝗼𝗻𝗲 𝗴𝗿𝗮𝗳𝘁 𝘁𝗵𝗮𝘁 𝗶𝘀 𝗽𝗿𝗼𝘃𝗲𝗻 𝘁𝗼 𝘀𝘁𝗮𝘆 𝗽𝘂𝘁 - with no mixing required. ¹ However, inadequate containment of water-soluble carriers like those found in P-15 Peptide grafts could result in product migration from the intended implantation site. ² MagnetOs sticks where you place it – in all putty formulations. Discover how → https://lnkd.in/e5GvEf5s

Are all bone grafts equal? 𝗬𝗼𝘂 𝗯𝗲 𝘁𝗵𝗲 𝗷𝘂𝗱𝗴𝗲… All MagnetOs™ formulations are cleared for use in both PLF (with level 1 data to support bone growth); and in any interbody space (cervical, thoracic, lumbar). * Unlike P-15 Peptides, which are currently only approved in the United States for single-level ACDF – a procedure recognized as having high fusion rates. ¹ 𝗦𝘁𝗮𝘆 𝗼𝗻 𝗹𝗮𝗯𝗲𝗹 𝘄𝗶𝘁𝗵 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀. Click here to view the results from our latest level 1 human clinical trial ² → https://lnkd.in/gdv5tnhQ To learn more about Project Fusion, click here → https://lnkd.in/gRajBqC7

Last month, Kuros Biosciences hosted our first Global Gathering in Atlanta, GA. Global Gatherings are held twice a year at Kuros, and the entire company is invited to listen to our leadership team provide updates throughout the organization. This Global Gathering was hosted at Truist Park, home of the Atlanta Braves Major League Baseball team. The meeting was followed by an entertaining scavenger hunt around the stadium filled with strategizing, bonding, and laughs! Interesting in joining our team? View our open job listings here → https://lnkd.in/g2H_HwxX

Kuros Biosciences is thrilled to share the peer-reviewed publication of MagnetOsᵀᴹ MAXA Level 1 Study Outcomes in Spine, 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗻𝗴 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗼𝘃𝗲𝗿 𝗮𝘂𝘁𝗼𝗴𝗿𝗮𝗳𝘁. The published clinical results include fusion data on 91 patients and 128 segments with 1-year follow up after surgery. In the challenging posterolateral fusion (PLF) model, MagnetOs achieved nearly double the fusion rate as compared to autograft showing a 𝟳𝟵% 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝗳𝘂𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 𝗰𝗼𝗺𝗽𝗮𝗿𝗲𝗱 𝘁𝗼 𝟰𝟳% 𝗳𝗼𝗿 𝗮𝘂𝘁𝗼𝗴𝗿𝗮𝗳𝘁. The data demonstrated noninferiority of MagnetOs versus autograft per study design, with 𝗽𝗿𝗶𝗺𝗮𝗿𝘆 𝗼𝘂𝘁𝗰𝗼𝗺𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗲𝘃𝗲𝗻 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗻𝗴 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿𝗶𝘁𝘆. Moyo C. Kruyt, MD, PhD, lead researcher in the MAXA study shared, “We are extremely pleased to share the results of the MAXA study with the medical community. The MAXA study demonstrates for the first time that an advanced synthetic bone substitute likely performs better than the current gold standard autograft in a challenging posterolateral fusion location.” The publication, which includes additional details such as study design, patient demographics, inclusion/exclusion criteria, and complications reported in the study, can be accessed on the 𝙎𝙥𝙞𝙣𝙚 website → https://lnkd.in/e8bMwfwa The publication is also available on the Kuros Biosciences website → https://lnkd.in/gRajBqC7 To read the full press release, click here → https://lnkd.in/e-s4nCdr

To those attending this year's State of Spine Surgery Think Tank conference, be sure to mark your calendar on 𝗙𝗿𝗶𝗱𝗮𝘆, 𝗝𝘂𝗻𝗲 𝟮𝟭𝘀𝘁, 𝟮𝟬𝟮𝟰 𝗳𝗿𝗼𝗺 𝟵:𝟮𝟬-𝟵:𝟮𝟲𝗮𝗺 for a presentation from 𝗗𝗿. 𝗧𝗵𝗼𝗺𝗮𝘀 𝗖𝗵𝗮, Associate Professor of Orthopedic Surgery at Rothman Institute, Sidney Kimmel Medical College / Thomas Jefferson University Hospital on the recently published Level 1 human clinical trial. Dr. Cha's presentation is titled 'Favorable Results of MagnetOsᵀᴹ as Standalone Alternative to Autograft in a Prospective, Multi-center, Randomized, Intra-patient Controlled Trial.' #spine #stateofspinesurgerythinktank #kurosbiosciences #Level1Data

Last week Kuros Biosciences hosted an in-person team meeting at our US corporate office in Atlanta, GA. This meeting was filled with lively discussions and inspiring updates across the company.   Congratulations to our 2023 award winners who were recognized at this event and are pictured below! Your dedication, hard work, and passion for excellence do not go unnoticed.   Breakout Performance - Nick Gambino Sales MVP - Mat Kandell Top Revenue Producer - Maggie Brabbins BSN, RN   Interesting in joining our team? View our open job listings here → https://lnkd.in/eHTwPnNz

Kuros Biosciences is honored to be featured in an article published by the Finanz und Wirtschaft, a prestigious Swiss journal that discusses topics relevant to investors.   The article highlights the great success of Kuros in the biologics market and subsequently the stock market. Kuros has seamlessly continued to grow from 2023 and the share price has more than tripled (+235%), increasing 80% following the announcement of the Q1 sales figures. In March 2024, the shares were trading at 5 francs and are currently sitting at 12 francs, a significant increase in less than three months.   CEO Chris Fair is optimistic about the course of business so far in the second quarter: "We are on track in the USA, and the expansion outside the USA is also going very well." In addition, CFO Daniel Geiger highlights that the new share price demonstrates the increased confidence of the financial market: "The company was previously completely undervalued. In recent months and weeks, we have moved closer to the area that many see as fair and are now registering much more interest from institutional investors."   Below is an English translated version of the article for your view to learn more about our successes of 2024. To read the original German version of this article, click here: https://lnkd.in/eQK2aKgX

Will you be attending this year's State of Spine Surgery Think Tank conference in San José del Cabo, Mexico? Visit the Kuros booth where you can explore the recent Level 1 human clinical data featuring MagnetOsᵀᴹ and discover our innovative NeedleGripᵀᴹ surface technology. #stateofspinesurgerythinktank #MagnetOs #Level1Data

Will you be attending this year's SFCR conference in Montpellier, France? Visit us at booth #9 where you can explore the recent Level 1 human clinical data featuring MagnetOsᵀᴹ and discover our innovative NeedleGripᵀᴹ surface technology. #spine #SFCR #kurosbiosciences